Pancreatic acinar cell cystadenocarcinoma

Summary

Pancreatic acinar cell cystadenocarcinoma (MONDO:0004343) is a disease. A subtype of pancreatic cystadenocarcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	pancreatic acinar cell cystadenocarcinoma
Mondo ID	MONDO:0004343
DOID	DOID:7729
NCIT	C5727
UMLS	C1266087
MedGen	224757
GARD	0023946
Is cancer (heuristic)	no

Also known as: acinar cell cystadenocarcinoma · acinar cell cystadenocarcinoma (morphologic abnormality) · acinar cell cystadenocarcinoma of pancreas · acinar cell cystadenocarcinoma of the pancreas · pancreatic acinar cell cystadenocarcinoma

Disease family

This is a subtype of pancreatic cystadenocarcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › adenocarcinoma › cystadenocarcinoma › pancreatic cystadenocarcinoma › pancreatic acinar cell cystadenocarcinoma

Related subtypes (2): pancreatic serous cystadenocarcinoma, pancreatic mucinous cystadenocarcinoma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.